| アブストラクト | BACKGROUND: The clinical and economic burden of long COVID is poorly understood. We aim to assess all-cause healthcare resource utilization (HCRU) and costs in the primary care setting among adults with long COVID in France. METHODS: A retrospective cohort study using the electronic healthcare records (EHRs) of confirmed and/or probable COVID-19 patients from The Health Improvement Network (THIN) data between March 2020 and December 2022 was conducted. Long COVID was identified per World Health Organization (WHO) definition as suggestive symptoms present >/=3 months following acute SARS-CoV-2 infection. Patients' characteristics, HCRU, direct healthcare and indirect costs (National Health Insurance-based prices) were summarized. Costs between patients with previous SARS-CoV-2 infection who developed long COVID, patients with previous SARS-CoV-2 infection who did not develop long COVID (COVID only), and contemporaneous controls without SARS-CoV-2 infection were compared (Non-COVID). RESULTS: Long COVID developed among 30,122 (11.6%) adults; mean (SD) age was 50 (17) years, 63.6% were female and 27.5% had a Charlson Comorbidity Index score >2. During the post-infection follow-up (mean = 13 months), 97.3% of patients had general practitioner consultations (GP) and 62.4% had nursing care. Costs were highest during the first post-diagnosis year with per patient per year costs of euro2,443 (total cost of euro52 million), including costs for GP (euro208) and specialist (euro170) consultations, outpatient procedures (euro413), retail pharmacy use (euro595), biological testing (euro147), and medical device usage (euro172). Patients with long COVID had additional costs of euro163 and euro176 when compared to patients in the COVID only and Non-COVID cohorts, respectively. LIMITATIONS: Since the THIN database is generated from GP EHRs, there is the possibility of measurement/documentation errors and missing values which could compromise the validity and accuracy of certain results. CONCLUSION: Long COVID was associated with non-negligible HCRU, direct and indirect costs to the French healthcare system. These findings reinforce the importance of optimizing long-term resource allocation for patients infected with SARS-CoV-2. |
|---|
| ジャーナル名 | Journal of medical economics |
|---|
| Pubmed追加日 | 2025/3/31 |
|---|
| 投稿者 | Yang, Jingyan; Tamberou, Cheikh; Arnee, Elise; Squara, Pierre-Alexandre; Boukhlal, Ayoub; Nguyen, Jennifer L; Volkman, Hannah R; Fievez, Stephane; Lepoutre-Bourguet, Marina; Ren, Jinma; Ben Romdhane, Haifa; Crepey, Pascal; Robineau, Olivier |
|---|
| 組織名 | Global Access and Value, Pfizer Inc., New York, NY, USA.;Institute for Social and Economic Research and Policy, Columbia University, New;York, NY, USA.;Real-World Evidence, GERS DATA, Paris, France.;Pfizer SAS, Paris, France.;Global Scientific Affairs, Pfizer Inc., New York, NY, USA.;Statistics Group, Pfizer Inc., Collegeville, PA, USA.;EHESP, CNRS, Inserm, University of Rennes, Rennes, France.;Inserm, Institut Pierre Louis d'Epidemiologie et de Sante Publique, Sorbonne;Universite, Paris, France.;Centre hospitalier Gustave Dron, EA2694, Centre Hospitalier de Tourcoing,;University Lille, Tourcoing, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40162934/ |
|---|
